A novel NMDA receptor glycine-site partial agonist, GLYX-13, has therapeutic potential for the treatment of autism

Neuroscience and Biobehavioral Reviews

Volumn 35, Issue 9, 2011, Pages 1982-1988

  Moskal, Joseph R ^a   Burgdorf, Jeffrey ^a   Kroes, Roger A ^a   Brudzynski, Stefan M ^b   Panksepp, Jaak ^a,c  

^a Northwestern University   (United States)

^b BROCK UNIVERSITY   (Canada)

^c WASHINGTON STATE UNIVERSITY   (United States)

Author keywords

Autism; GLYX 13; Microarray; NMDA; Rats; Rough and tumble play; Vocalizations

Indexed keywords

ANIMALS; AUTISTIC DISORDER; BRAIN CHEMISTRY; ENDORPHINS; GENE EXPRESSION; HUMANS; OLIGOPEPTIDES; PLAY AND PLAYTHINGS; RATS; RECEPTORS, GLYCINE; RECEPTORS, N-METHYL-D-ASPARTATE; VOCALIZATION, ANIMAL;

EID: 80053108650     PISSN: 01497634     EISSN: 18737528     Source Type: Journal    
DOI: 10.1016/j.neubiorev.2011.06.006     Document Type: Review

References (63)

1. Borneman A.R., Leigh-Bell J.A., Yu H., Bertone P., Gerstein M., Snyder M. Target hub proteins serve as master regulators of development in yeast. Genes Dev. 2006, 20:435-448.
2. Bouvard M.P., Leboyer M., Launay J.M., Recasens C., Plumet M.H., Waller-Perotte D., Tabuteau F., Bondoux D., Dugas M., Lensing P., et al. Low-dose naltrexone effects on plasma chemistries and clinical symptoms in autism: a double-blind, placebo-controlled study. Psychiatry Res. 1995, 58:191-201.
3. Brambilla F., Guareschi-Cazzullo A., Tacchini C., Musetti C., Panerai A.E., Sacerdote P. Beta-endorphin and cholecystokinin 8 concentrations in peripheral blood mononuclear cells of autistic children. Neuropsychobiology 1997, 35:1-4.
4. Brown N., Panksepp J. Low-dose naltrexone for disease prevention and quality of life. Med. Hypotheses 2009, 72:333-337.
5. Burgdorf J., Kroes R.A., Beinfeld M.C., Panksepp J., Moskal J.R. Uncovering the molecular basis of positive affect using rough-and-tumble play in rats: a role for insulin-like growth factor I. Neuroscience 2010, 168:769-777.
6. Burgdorf J., Kroes R.A., Moskal J.R., Pfaus J.G., Brudzynski S.M., Panksepp J. Ultrasonic vocalizations of rats (Rattus norvegicus) during mating, play, and aggression: Behavioral concomitants, relationship to reward, and self-administration of playback. J. Comp. Psychol. 2008, 122:357-367.
7. Burgdorf J., Panksepp J. The neurobiology of positive emotions. Neurosci. Biobehav. Rev. 2006, 30:173-187.
8. Burgdorf J., Panksepp J., Brudzynski S.M., Beinfeld M.C., Cromwell H.C., Kroes R.A., Moskal J.R. The effects of selective breeding for differential rates of 50-kHz ultrasonic vocalizations on emotional behavior in rats. Dev. Psychobiol. 2009, 51:34-46.
9. Burgdorf J., Panksepp J., Brudzynski S.M., Kroes R., Moskal J.R. Breeding for 50-kHz positive affective vocalization in rats. Behav. Genet. 2005, 35:67-72.
10. Burgdorf J., Westrich L., Sprouse J., Moskal J.R. The antidepressant and anxiolytic properties of GLYX-13: a novel NMDA receptor glycine site functional partial agonist. Soc. Neurosci. Annu. Meet. 2010, 572.:523.
11. Burgdorf J., Wood P.L., Kroes R.A., Moskal J.R., Panksepp J. Neurobiology of 50-kHz ultrasonic vocalizations in rats: electrode mapping, lesion, and pharmacology studies. Behav. Brain Res. 2007, 182:274-283.
12. Burgdorf J., Zhang X.L., Weiss C., Matthews E., Disterhoft J.F., Stanton P.K., Moskal J.R. The N-methyl-d-aspartate receptor modulator GLYX-13 enhances learning and memory, in young adult and learning impaired aging rats. Neurobiol. Aging 2011, 23:3698-3706.
13. Carlsson M.L. Hypothesis: is infantile autism a hypoglutamatergic disorder? Relevance of glutamate - serotonin interactions for pharmacotherapy. J. Neural Transm. 1998, 105:525-535.
14. Cazzullo A.G., Musetti M.C., Musetti L., Bajo S., Sacerdote P., Panerai A. Beta-endorphin levels in peripheral blood mononuclear cells and long-term naltrexone treatment in autistic children. Eur. Neuropsychopharmacol. 1999, 9:361-366.
15. CDC Prevalence of autism spectrum disorders - Autism and Developmental Disabilities Monitoring Network, United States, 2006. MMWR Surveill Summ. 2009, 58:1-20.
16. Chez M.G., Burton Q., Dowling T., Chang M., Khanna P., Kramer C. Memantine as adjunctive therapy in children diagnosed with autistic spectrum disorders: an observation of initial clinical response and maintenance tolerability. J. Child Neurol. 2007, 22:574-579.
17. Ciucci M.R., Ahrens A.M., Ma S.T., Kane J.R., Windham E.B., Woodlee M.T., Schallert T. Reduction of dopamine synaptic activity: degradation of 50-kHz ultrasonic vocalization in rats. Behav. Neurosci. 2009, 123:328-336.
18. Elchaar G.M., Maisch N.M., Augusto L.M., Wehring H.J. Efficacy and safety of naltrexone use in pediatric patients with autistic disorder. Ann. Pharmacother. 2006, 40:1086-1095.
19. Gillberg C., Terenius L., Lonnerholm G. Endorphin activity in childhood psychosis. Spinal fluid levels in 24 cases. Arch. Gen. Psychiatry 1985, 42:780-783.
20. Green J.J., Hollander E. Autism and oxytocin: new developments in translational approaches to therapeutics. Neurotherapeutics 2010, 7:250-257.
21. Haring R., Stanton P.K., Scheideler M.A., Moskal J.R. Glycine-like modulation of N-methyl-d-aspartate receptors by a monoclonal antibody that enhances long-term potentiation. J. Neurochem. 1991, 57:323-332.
22. Hyman S.E. Can neuroscience be integrated into the DSM-V?. Nat. Rev. Neurosci. 2007, 8:725-732.
23. Jesner O.S., Aref-Adib M., Coren E. Risperidone for autism spectrum disorder. Cochrane Database Syst. Rev. 2007, CD005040.
24. Keverne E.B., Martensz N.D., Tuite B. Beta-endorphin concentrations in cerebrospinal fluid of monkeys are influenced by grooming relationships. Psychoneuroendocrinology 1989, 14:155-161.
25. King B.H., Wright D.M., Handen B.L., Sikich L., Zimmerman A.W., McMahon W., Cantwell E., Davanzo P.A., Dourish C.T., Dykens E.M., Hooper S.R., Jaselskis C.A., Leventhal B.L., Levitt J., Lord C., Lubetsky M.J., Myers S.M., Ozonoff S., Shah B.G., Snape M., Shernoff E.W., Williamson K., Cook E.H. Double-blind, placebo-controlled study of amantadine hydrochloride in the treatment of children with autistic disorder. J. Am. Acad. Child Adolesc. Psychiatry 2001, 40:658-665.
26. Kolmen B.K., Feldman H.M., Handen B.L., Janosky J.E. Naltrexone in young autistic children: replication study and learning measures. J. Am. Acad. Child Adolesc. Psychiatry 1997, 36:1570-1578.
27. Kroes R.A., Panksepp J., Burgdorf J., Otto N.J., Moskal J.R. Modeling depression: social dominance-submission gene expression patterns in rat neocortex. Neuroscience 2006, 137:37-49.
28. Leboyer M., Philippe A., Bouvard M., Guilloud-Bataille M., Bondoux D., Tabuteau F., Feingold J., Mouren-Simeoni M.C., Launay J.M. Whole blood serotonin and plasma beta-endorphin in autistic probands and their first-degree relatives. Biol. Psychiatry 1999, 45:158-163.
29. Lee S.A., Chan C.H., Chen T.C., Yang C.Y., Huang K.C., Tsai C.H., Lai J.M., Wang F.S., Kao C.Y., Huang C.Y. POINeT: protein interactome with sub-network analysis and hub prioritization. BMC Bioinform. 2009, 10:114.
30. Lovaas O.I. Behavioral treatment and normal educational and intellectual functioning in young autistic children. J. Consult. Clin. Psychol. 1987, 55:3-9.
31. Lovaas O.I., Simmons J.Q. Manipulation of self-destruction in three retarded children. J. Appl. Behav. Anal. 1969, 2:143-157.
32. Meyer-Lindenberg A., Weinberger D.R. Intermediate phenotypes and genetic mechanisms of psychiatric disorders. Nat. Rev. Neurosci. 2006, 7:818-827.
33. Moles A., Kieffer B.L., D'Amato F.R. Deficit in attachment behavior in mice lacking the mu-opioid receptor gene. Science 2004, 304:1983-1986.
34. Moskal J.R., Kuo A.G., Weiss C., Wood P.L., O'Connor Hanson A., Kelso S., Harris R.B., Disterhoft J.F. GLYX-13: a monoclonal antibody-derived peptide that acts as an N-methyl-d-aspartate receptor modulator. Neuropharmacology 2005, 49:1077-1087.
35. Munesue T., Yokoyama S., Nakamura K., Anitha A., Yamada K., Hayashi K., Asaka T., Liu H.X., Jin D., Koizumi K., Islam M.S., Huang J.J., Ma W.J., Kim U.H., Kim S.J., Park K., Kim D., Kikuchi M., Ono Y., Nakatani H., Suda S., Miyachi T., Hirai H., Salmina A., Pichugina Y.A., Soumarokov A.A., Takei N., Mori N., Tsujii M., Sugiyama T., Yagi K., Yamagishi M., Sasaki T., Yamasue H., Kato N., Hashimoto R., Taniike M., Hayashi Y., Hamada J., Suzuki S., Ooi A., Noda M., Kamiyama Y., Kido M.A., Lopatina O., Hashii M., Amina S., Malavasi F., Huang E.J., Zhang J., Shimizu N., Yoshikawa T., Matsushima A., Minabe Y., Higashida H. Two genetic variants of CD38 in subjects with autism spectrum disorder and controls. Neurosci. Res. 2010, 67:181-191.
36. Nakatani J., Tamada K., Hatanaka F., Ise S., Ohta H., Inoue K., Tomonaga S., Watanabe Y., Chung Y.J., Banerjee R., Iwamoto K., Kato T., Okazawa M., Yamauchi K., Tanda K., Takao K., Miyakawa T., Bradley A., Takumi T. Abnormal behavior in a chromosome-engineered mouse model for human 15q11-13 duplication seen in autism. Cell 2009, 137:1235-1246.
37. Panksepp J. A neurochemical theory of autism. Trends Neurosci. 1979, 2:174-177.
38. Panksepp J. Brain opioids: a neurochemical substrate for narcotic and social dependence. Progress in Theory in Psychopharmacology 1981, 149-175. Academic Press, London. Cooper (Ed.).
39. Panksepp J. Oxytocin effects on emotional processes: separation distress, social bonding, and relationships to psychiatric disorders. Ann. N. Y. Acad. Sci. 1992, 652:243-252.
40. Panksepp J. Affective Neuroscience: The Foundations of Human and Animal Emotions 1998, Oxford University Press, New York.
41. Panksepp J. Emotional endophenotypes in evolutionary psychiatry. Prog. Neuropsychopharmacol. Biol. Psychiatry 2006, 30:774-784.
42. Panksepp J., Herman B.H., Vilberg T., Bishop P., DeEskinazi F.G. Endogenous opioids and social behavior. Neurosci. Biobehav. Rev. 1980, 4:473-487.
43. Panksepp J., Lensing P., Leboyer M., Bouvard M.P. Naltrexone and other potential new pharmacological treatments of autism. Brain Dysfunction 1991, 4:281-300.
44. Panksepp J., Sahley T. Possible brain opioid involvement in disrupted social intent and language development of autism. Neurobiological Issues in Autism 1987, Plenum Press, New York. E. Schopler, G. Mesibov (Eds.).
45. Panksepp J.B., Jochman K.A., Kim J.U., Koy J.J., Wilson E.D., Chen Q., Wilson C.R., Lahvis G.P. Affiliative behavior, ultrasonic communication and social reward are influenced by genetic variation in adolescent mice. PLoS One 2007, 2:e351.
46. Panksepp J.B., Lahvis G.P. Social reward among juvenile mice. Genes Brain Behav. 2007, 6:661-671.
47. Parikh M.S., Kolevzon A., Hollander E. Psychopharmacology of aggression in children and adolescents with autism: a critical review of efficacy and tolerability. J. Child Adolesc. Psychopharmacol. 2008, 18:157-178.
48. Posey D.J., Kem D.L., Swiezy N.B., Sweeten T.L., Wiegand R.E., McDougle C.J. A pilot study of d-cycloserine in subjects with autistic disorder. Am. J. Psychiatry 2004, 161:2115-2117.
49. Purcell A.E., Jeon O.H., Zimmerman A.W., Blue M.E., Pevsner J. Postmortem brain abnormalities of the glutamate neurotransmitter system in autism. Neurology 2001, 57:1618-1628.
50. Ritvo E.R., Freeman B.J., Mason-Brothers A., Mo A., Ritvo A.M. Concordance for the syndrome of autism in 40 pairs of afflicted twins. Am. J. Psychiatry 1985, 142:74-77.
51. Rosenberg R.E., Law J.K., Yenokyan G., McGready J., Kaufmann W.E., Law P.A. Characteristics and concordance of autism spectrum disorders among 277 twin pairs. Arch. Pediatr. Adolesc. Med. 2009, 163:907-914.
52. Rossignol D.A. Novel and emerging treatments for autism spectrum disorders: a systematic review. Ann. Clin. Psychiatry 2009, 21:213-236.
53. Sandman C.A., Hetrick W., Talyor D., Marion S., Chicz-DeMet A. Uncoupling of proopiomelanocortin (POMC) fragments is related to self-injury. Peptides 2000, 21:785-791.
54. Silverman J.L., Yang M., Lord C., Crawley J.N. Behavioural phenotyping assays for mouse models of autism. Nat. Rev. Neurosci. 2010, 11:490-502.
55. Stanton P.K., Potter P.E., Aguilar J., Decandia M., Moskal J.R. Neuroprotection by a novel NMDAR functional glycine site partial agonist, GLYX-13. Neuroreport 2009, 20:1193-1197.
56. Symons F.J., Thompson A., Rodriguez M.C. Self-injurious behavior and the efficacy of naltrexone treatment: a quantitative synthesis. Ment. Retard. Dev. Disabil. Res. Rev. 2004, 10:193-200.
57. Thompson L.T., Moskal J.R., Disterhoft J.F. Hippocampus-dependent learning facilitated by a monoclonal antibody or d-cycloserine. Nature 1992, 359:638-641.
58. Tordjman S., Anderson G.M., McBride P.A., Hertzig M.E., Snow M.E., Hall L.M., Thompson S.M., Ferrari P., Cohen D.J. Plasma beta-endorphin, adrenocorticotropin hormone, and cortisol in autism. J. Child Psychol. Psychiatry 1997, 38:705-715.
59. Wing L., Gould J. Severe impairments of social interaction and associated abnormalities in children: epidemiology and classification. J. Autism Dev. Disord. 1979, 9:11-29.
60. Wohr M., Moles A., Schwarting R.K., DAmato F.R. Lack of social exploratory activation in male mu-opioid receptor KO mice in response to playback of female ultrasonic vocalizations. Soc. Neurosci. 2011, 6:76-87.
61. Wood P.L., Mahmood S.A., Moskal J.R. Antinociceptive action of GLYX-13: an N-methyl-d-aspartate receptor glycine site partial agonist. Neuroreport 2008, 19:1059-1061.
62. Yang M.S., Gill M. A review of gene linkage, association and expression studies in autism and an assessment of convergent evidence. Int. J. Dev. Neurosci. 2007, 25:69-85.
63. Zhang X.L., Sullivan J.A., Moskal J.R., Stanton P.K. A NMDA receptor glycine site partial agonist GLYX-13, simultaneously enhances LTP and reduces LTD at Schaffer collateral-CA1 synapses in hippocampus. Neuropharmacology 2008, 55:1238-1250.